LONG-ACTING INJECTABLES (LAIs)

In 2023, ADAP Advocacy launched a new patient-centric project addressing barriers to accessing HIV Long-Acting Injectables (LAIs) for the treatment of HIV, as well as LAIs for Pre-Exposure Prophylaxis (PrEP). The project addresses ongoing concerns expressed by patients being served under the AIDS Drug Assistance Programs (ADAPs), as well as other impacted populations with commercial insurance interested in LAIs for either HIV-related treatment or prevention. Click on the following links to download the project's executive summary and final report:

• Executive Summary – Patient Access Considerations for Injectable HIV Therapies & Injectable HIV Pre-Exposure Prophylaxis
• Final Report – Patient Access Considerations for Injectable HIV Therapies & Injectable HIV Pre-Exposure Prophylaxis

This patient-centric project Leads with Equity. Healthcare equity is paramount to ending the HIV epidemic; access to services and medications should be available to all who seek to manage HIV infection, regardless of their payer or insurance coverage; commercial, Medicaid, Medicare or ADAP. Additionally, medication accessibility is not the only lever to optimize health and outcomes; access to healthcare facilities and culturally competent providers vested in reducing health disparities are critically necessary components to furthering access and retention in care.